Development asset linked to Akeso in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
pharma · Advanced Malignant Tumors · Metastatic Pancreatic Ductal Adenocarcinoma
Akeso
Akeso drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
2012 Founded
112 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2012
- Employees
- 112
- Programs
- 3
- Drugs
- 8
- Patents
- 0
Akeso pipeline
Portfolio lens on 8 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Akeso drug portfolio — 8 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Akeso in public FDA and regional records.
-
Development asset linked to Akeso in public FDA and regional records.
-
Development asset linked to Akeso in public FDA and regional records. Molecular target: Cytotoxic T-lymphocyte protein 4.
- Target
- Cytotoxic T-lymphocyte protein 4
- Mechanism
- Cytotoxic T-lymphocyte protein 4 inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to Akeso in public FDA and regional records.
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to Akeso in public FDA and regional records.